Jump to content

Clocortolone pivalate

From Wikipedia, the free encyclopedia
Clocortolone pivalate
Clinical data
Trade namesCilder, Cloderm, Purantix
Other namesClocortolone trimethylacetate; CL-68; SH-863; 9α-Chloro-6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-pivalate
Drug classCorticosteroid; Glucocorticoid
Identifiers
  • [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-Chloro-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.047.099 Edit this at Wikidata
Chemical and physical data
FormulaC27H36ClFO5
Molar mass495.03 g·mol−1
3D model (JSmol)
  • C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)Cl)C)F
  • InChI=1S/C27H36ClFO5/c1-14-9-16-17-11-19(29)18-10-15(30)7-8-26(18,6)27(17,28)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,10,14,16-17,19,21-22,32H,9,11-13H2,1-6H3/t14-,16+,17+,19+,21+,22-,25+,26+,27+/m1/s1
  • Key:SXYZQZLHAIHKKY-GSTUPEFVSA-N

Clocortolone pivalate (brand names Cilder, Cloderm, Purantix), also known as clocortolone trimethylacetate, is a synthetic glucocorticoid corticosteroid and corticosteroid ester which is marketed in the United States and Austria.[1][2][3] It is the C21 pivalate (trimethylacetate) ester of clocortolone,[1][2] and acts as a prodrug of clocortolone in the body.[4][5]

References

[edit]
  1. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 293–. ISBN 978-1-4757-2085-3.
  2. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 253–. ISBN 978-3-88763-075-1.
  3. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 79–. ISBN 978-94-011-4439-1.
  4. ^ US 5073641, Bundgaard H, Nielsen NM, "Prodrug derivatives of carboxylic acid drugs", issued 17 December 1991 
  5. ^ Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J (12 March 2007). Prodrugs: Challenges and Rewards. Springer Science & Business Media. pp. 220–. ISBN 978-0-387-49782-2.